RxDoctor Payments Data

Barton Wachs, MD

Urology · Long Beach, CANPI 1366461832

Payments from drug & device makers

$106,602in general payments, 2019–2025

Across 370 payments — averaging $288.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$66K
  • Ipsen Innovation$30K
  • Angiodynamics, Inc.$2K
  • Astellas Pharma US Inc$1K
  • Boston Scientific$935
  • Agiliti Surgical, Inc.$803
  • plus $6K from 46 others

What the payments were for

  • Travel & lodging$1,0029%
  • Food & beverage$9,08784%
  • Education$6766%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$106,602 in reported general payments places this provider in the 90th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$162,912
Medicare patients
422
Services billed
1,891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron286$199,392
GemtesaVibegron60$50,135
PremarinEstrogens, Conjugated56$23,766
Terazosin Hcl693$12,444
Estradiol135$8,809
Mirabegron ErMirabegron21$7,028
Tamsulosin Hcl486$6,274
Finasteride331$4,868
Potassium Citrate ErPotassium Citrate35$4,210
Bicalutamide93$3,137
Oxybutynin Chloride ErOxybutynin Chloride89$2,459
NitrofurantoinNitrofurantoin Macrocrystal98$2,332
Methenamine Hippurate16$1,222
Ciprofloxacin Hcl260$721
Solifenacin Succinate11$645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,275$199,392286 claims
Sumitomo Pharma America, Inc.Gemtesa$489$50,13560 claims
PfizerPremarin$790$23,76656 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,324 urology providers in California.

Other urology in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →